Biocon has reported results for fourth quarter (Q4) and year ended March 31, 2024.
The company has reported 99.23% fall in its net profit at Rs 14.00 crore for the quarter under review as compared to Rs 1810.80 crore for the same quarter in the previous year. However, total income of the company increased by 0.14% at Rs 571.50 crore for Q4FY24 as compared Rs 570.70 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 46.22% fall in its net profit at Rs 222.90 crore for fourth quarter ended March 31, 2024 as compared to Rs 414.50 crore for the same quarter in the previous year. However, total income of the company increased by 0.94% at Rs 3965.70 crore for Q4FY24 as compared Rs 3928.80 crore for the corresponding quarter previous year.
For the year ended March 31, 2024, the company has reported 95.81% fall in its net profit at Rs 119.30 crore as compared to Rs 2848.40 crore for the previous year. However, total income of the company increased by 2.47% at Rs 2320.30 crore for year under review as compared to Rs 2264.30 crore for year ended March 31, 2023.
For the year ended March 31, 2024, on the consolidated basis, the company has reported 2- fold jump in its net profit at Rs 1297.80 crore as compared to Rs 643.00 crore for the previous year. Total income of the company increased by 35.25% at Rs 15621.20 crore for year under review as compared to Rs 11550.10 crore for year ended March 31, 2023.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1462.50 |
Dr. Reddys Lab | 5784.50 |
Cipla | 1451.25 |
Zydus Lifesciences | 1001.15 |
Lupin | 1587.90 |
View more.. |